Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TPH1 | P17752 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396216 | 0.90 | HSP90AA1 (0.56) | HDAC6HDAC1HDAC4HSP90AA1HDAC2 | |
| SCHEMBL3393621 | 0.87 | SLC2A1 (0.58) | HDAC6HDAC1HDAC4HSP90AA1HDAC2 | |
| SCHEMBL17262807 | 0.86 | HDAC1 (0.50) | HDAC6HDAC1HDAC4HSP90AA1HDAC2 | |
| SCHEMBL3391551 | 0.83 | HSP90AA1 (0.68) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL3390553 | 0.83 | HSP90AA1 (0.65) | HDAC6HDAC1HDAC4HSP90AA1HDAC2 | |
| SCHEMBL1716546 | 0.82 | HDAC6 (0.64) | HDAC6HDAC1HDAC4HSP90AA1HDAC2 | |
| SCHEMBL3423730 | 0.80 | HDAC6 (0.62) | HDAC6HDAC1HDAC4HSP90AA1HDAC2 | |
| SCHEMBL10195513 | 0.79 | NPSR1 (0.50) | HDAC6HSP90AA1NPSR1ADORA2AHSP90AB1 | |
| SCHEMBL5460397 | 0.78 | ABL1 (0.57) | TPH1 | |
| SCHEMBL10195525 | 0.78 | HSP90AA1 (0.60) | HSP90AA1NPSR1ADORA2AHSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070173483-A1 | Pyrrolopyrimidines and Related Analogs as HSP90-Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173483-A1 | Pyrrolopyrimidines and Related Analogs as HSP90-Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173483-A1 | Pyrrolopyrimidines and Related Analogs as HSP90-Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-26 | — | — | US | disclosed |
| US-7138402-B2 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050107343-A1 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION | 2005-05-19 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107343-A1 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | HDAC6 395/4885HDAC1 1268/4885HDAC4 1668/4885 |
| US-20070173483-A1 | Pyrrolopyrimidines and Related Analogs as HSP90-Inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | HDAC6 395/4885HDAC1 1268/4885HDAC4 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.